Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1
  • 2

proteome sciences........opinions (PRM)     

fisherboy - 10 Mar 2008 08:49

Does anyone have an opinion on PRM.
No comparable news for a while.
Price seems to be sliding once again.

Snodders Junior - 09 Jul 2008 08:33 - 17 of 37

I predict a BIG ANNOUNCEMENT soon

Silent Service - 02 Aug 2008 07:52 - 18 of 37

Market Reaction in last two days seems to indicate something coming VERY SOON.

Toya - 02 Aug 2008 21:01 - 19 of 37

Something's going on for sure - two lots of Price Monitoring Extensions on Thurs and Fri of this week, and sp shot up. Just can't think what's going on as I've not followed this for a while, though did notice the rise in last couple of days. Think I may leap back on board first thing Monday.

Toya - 04 Aug 2008 07:51 - 20 of 37

... on second thoughts: sp is indicating down this morning. Will keep an eye on it

hangon - 26 Aug 2008 09:27 - 21 of 37

No obvious NEWs yet - so what caused the big rise ( almost doubled!).?
Maybe a perception that this technology has some merit and will be big one day. Maybe it's a better understanding of the Dir-Loan (being in Shareholder interest?) and so on.
Without solid news this could slip back as folk depart, taking a small profit as is tempting.....or do you hang-on in there to reaqp the potential rewards?

This Co has always told the Market there is a Big-Deal round the corner...and maybe one day there will be.
What's odd, is that with a technology so good - why aren't Drug-Co's snapping them up? . . . . . . that remains a worry, but IF there is a good deal - then this should multiply - I have a small holding from c. sub30p and somewhat more higher...I guess I might be near-evens currently, but if it goes well, I shall be happy enough.
Current Markets strip-out losers....just hope this survives OK.

I'm not feeding this one....waiting will do.

bluemango - 26 Aug 2008 10:02 - 22 of 37

"What's odd, is that with a technology so good - why aren't Drug-Co's snapping them up?"

The director loan and its current terms involving the IP and potential conversion are in effect a 'poison pill' for any would-be predator. CJP's game-plan will probably involve an agreed takeover at some future time, but not before full value has been added. The two main cash inflows still to come are, firstly, sub-licences from current infringers of the TMT patents thus allowing TF and PRM to tap into current/future royalty streams, plus a large element for back-royalties due to PRM. Secondly they are still pursuing a 30m euros warranties claim with Sanofi-Aventis. Both could result in multi-million windfall payments to Proteome, and may be a motivation behind some of the recent buying.

This is all quite apart from possible commercial deals for HTS biomarkers and for Alzheimer's biomarkers.

Nothing new in the above of course, which is why the Company still have something of a credibility hill to climb. So until any of the above actually occur, there's still an element of gamble here, but with corporate activity involving ABI this Autumn, the odds are at last looking to shift in Proteome's favour.

hangon - 01 Sep 2008 10:37 - 23 of 37

Bluemango, yes I agree about that loan - yet the story from the company was started nearly ten years ago - so why didn't any Big Pharma want it then?....mainly punters bought shares . . . and that was the start of their/our woes.

Seems to me that many large-Co's don't look to their furture. By watching nascent technologies they might be able to ride the wave well into the future. No, I'm not suggesting a buy-out, just a "initerest" with maybe some assistance by way of Management expertise...

So, let's hope it is starting to come true, eh?

bluemango - 03 Sep 2008 12:34 - 24 of 37

Big pharma tend to be ultra-cautious and move at absolute snail pace. They certainly wouldn't have risked resources on unproven technology ten years ago, particularly bearing in mind this would have been before PRM acquired the rights to the TMT technology via Xzillion.

Now, they are also still unlikely to make a move while, in theory, the patent situation is on the face of it unclear with an ABI objection to PRM's patent still outstanding. However the key to movement here will be EPO clarification of the patent situation (unless Invitrogen/ABI decide to settle beforehand) and with Thermo Fisher then obtaining a license from ABI - with back-royalties due to PRM dating back to 2004.

hangon - 03 Oct 2008 11:39 - 25 of 37

This Patent-issue is a worry, that after so long we discover there is a broken patio-door round the back of the castle. Tad careless, or is this "claim" opportunistic I wonder. This is unlikely since no professionals would associate themselves with a trivial claim, so I suspect it has some merit, however small. This will drag on the shares, although this morming they are up on "no-news".
We'll just have to wait a lot longer, I fear.

Obe2konobi - 07 Oct 2008 18:49 - 26 of 37

Such Pessimism from the pair of you. I say the pair of you because this has to be one of the least used boards on the Proteome saga. I have only held shares for a relitely short period of their history but have held long enough to see them swing from 45p down to 18 or so then right back up to 42 recently. All the while wishing I had a crystal ball to take advantage of what for some was a 100% gain within around two weeks.
I hear what your saying Hangon regarding the patent issue but lets not forget that Thermo Fisher came on board already knowing that ABI were challenging again. I think I am correct in saying again as I believe Proteome has already won in court regarding the Patents once. This challenge is little different from the first lost case for ABI and this I believe is why Thermo Fisher are happy to be on board before the result of what they can only judge to be another win for Proteome. These people have the best legal advice possible and they would have done there own extensive research into the possibilities of loosing this challenge. It seems like mere/sour grapes stalling tactics on ABI's behalf.
As Bluemango suggested, it may get settled beforehand to avoid more costs than already mounting. At the time ABI didn't know that Thermo Fisher was going to go on board with proteome and may have thought that a long drawn out challenge could have seen the back of Proteome or a buy out. Just my thoughts.
I think the next six months will bare fruit...how much in this insanely turbulent market is anybodies guess. Good news these days can see a healthy days gain only to be forgotten and lost a few days after for no other reason than blind panic selling or "market conditions" ! A lovely saying for those companies with little to do with any of the recent problems seeing their value slide away as if they were the cause of it.....I'm not bitter !!! :o) Obe2

hangon - 24 Oct 2008 16:24 - 27 of 37

Obe2konobi , Yes I think much of what you say about the Legal issue could be true - "opportunism" -
However, this dismisses the key issue that they are always supposed to be "near" a deal yet even with Fisher there seems to be Great Silence.

My understanding is that "proetomics" give a clear indication to the correct drug-treatment; explaining variations in patients taking the same stuff, etc. so why isn't this Red-Hot? [EDIT:-However, I'm wondering if it has the ability to create more information than is good for us - for example a pH-test gives a colour and you compare this agqainst a chart. If however you put the test-strip into a machine which prints out the whole works of shakespere (as it were), you have more work to do and a lot more time is wasted, etc.].
Think of the money the NHS spends; which by correct "targeting" the effects could double, say ....and it should be evident the NHS requires half the drugs, since they don't give patients the "wrong stuff".
However, I'm not sure that PRM is "yet" at this simplistic stage, rather like in the early days of photography, B&W is nice but colour would be better, then along come PRM with a process that gives you colour - except they only have yellow.......very exciting I don't think....and until PRM manages to convey what it's got ( to shareholders) they will be stuck in this yo-yo region, drifting now because of the general-woes.

And still there is silence . . . just how long do shareholders have to wait for some return? . . . . . Grr.

EDIT -(18Jn09)-Oh deary, result out and sp falls . . . . you have to wonder at the patience of shareholders in this kingdom.

hlyeo98 - 24 Jan 2010 19:29 - 28 of 37

Chart.aspx?Provider=EODIntra&Code=PRM&Si

hangon - 25 May 2010 15:04 - 29 of 37

I think they need to empty the fridges in the executive suite wherever they sleep.
(that's where the smell is)
Good to read that Share-Options are still considered part of Exec. pay . . . . . . .........Grr.
(This stock has lost 2/3 value since 2007 - DYOR -) - 24p mid today on small trades, nearly even despite a 10% push by MM's.
EDIT (20Nov2010)- SP has risen, presumably a few months of no bad News - we needed it!, now 36p-ish DYOR.
EDIT (11Feb2011) -slipped to 34p after a rise, due to Jan Contract win.
EDIT (5Sept2013)-; Yawn,- Peaked 70p 2013 now dn at 46p . . . oh deary, how dreary . . .
((EDIT))Dec2016...Looking back 10years - easily 90% Club - it's now 5.5p

hangon - 18 Nov 2011 14:32 - 30 of 37

Thought I'd post again . . . but nowt to say - this Co. is a thorough disappointment.
27p-ish
EDIT Jan2017 - now about 5p. . . . hopeless.

samsun - 28 Jun 2013 16:12 - 31 of 37

Some good news today and rising from a very low point now 42.25p

Chart.aspx?Provider=EODIntra&Code=PRM&Si

samsun - 28 Jun 2013 16:19 - 32 of 37

28 June 2013 AGM

Proteome Sciences expects a sharp increase in group revenue in 2013, the company's annual general meeting statement says.

The group says its commercial activities are benefiting from its technology development and the rapid increase in the numbers of biomarkers covered by its assays that doubled to over 100 in 2012.

It says SysQuant cell signalling pathway assays introduced this year will extend these further and should make a considerable contribution to the assay portfolio. This is reflected in biomarker services in revenue particularly through the major strategic contract announced earlier this month and through a broad and growing pipeline of contracts, enquiries and quotations.

Proteome Sciences says licensing discussions are expected to benefit from the excellent results coming through this year from CK1D that will be presented at the main Alzheimer's meeting in July, strongly supported by the considerable improvement in performance from two new peptide panels announced in the preliminary results for Alzheimer's disease and mild cognitive impairment (MCI), with further developments anticipated from our stroke biomarkers.

Outstanding data was presented at the June ASMS meeting using TMT which now appears to be established as the reagent of choice for key opinion leaders in the field. The growing range of products and applications should accelerate and convert more widely the use of TMT into mainstream biology and additional revenue. Proteome Sciences says it has again been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in the light of recent US court rulings on patent eligibility, in particular the court's recent ruling against Myriad that patents will not be allowed on genes.

Proteome Sciences says this has no bearing on the company's intellectual property.

And it says shareholders will be pleased to know that the company received subsequent notification this week from the US Patent and Trademark Office of the allowance of a new patent in Huntington's disease.

It adds: "We conclude that these decisions do not change the status of our issued and pending US applications or impact our granted US patents which continue to remain in good standing.

"We expect a strong performance over the year from licences, products and services as we continue to raise our corporate and research profile and this should lead to a sharp increase in Group revenue in 2013."

Claretdabbler - 30 Sep 2013 10:25 - 33 of 37

I have gone grey waiting for the sharp rise in revenue to beat the even sharper rise in losses!

Claretdabbler - 11 Dec 2013 13:05 - 34 of 37

It seems that Alzheimers could be detected 10 years before the symptoms appear if suitable biomarkers are employed. I gather that the Government are keen to fund the
work as ,although there is no cure yet available,the dementia can be largely mitigated
if found soon enough.Cameron has just doubled the grants available.I had to look after my father for 6 years of dementia and I really hope I am not going down that road.
I am back in.

hangon - 13 Jan 2014 23:23 - 35 of 37

What would be the point of detecting Az 10 years beforehand? - And how do they know? Surely the body is so complex you could die of something else and then the detection would be - pointless. Of course if it was cheap, then maybe - but I don't know the price-point of these "markers" - and I suspect they aren't cheap.
Anyone know?

The trouble with this co (investment) appears to be that investors never benefit from all this good medicine. As to Government being keen - I discount this as Political posturing - otherwise they'd be spending money - but the mantra of NHS is to Cut, Cut, Cut - so I don't see where PRM is going to get acceptable income from UK/NHS.
This co. is a serial disappointment IMHO.
EDIT: (25March2014)...35p &+ve movement, but recent ( Feb14), Placing at 28p was a further blow to earlier investors. I see CP has bought 4m shares since 2008.
EDIT (Oct2014) Looks like Mr Diggle likes this company as well as OXB - appears to have LT investment for his Life-Sciences fund....DYOR. sp now 31p
EDIT ( 20Jan2015 ) NHS cuts cancer-drug funding for patients, PRM sp 25p
EDIT (31March2015)- earlier iin March more agreements signed-plus US Patent granted -DYOR- sp is 19p - Oh deary..... where's the money?
EDIT (2June2015 )-Oh deary, looks like 2014-Sales barely £1m and losses stack up to £60m - DYOR - looks pretty thin for Investor returns.... yet-awhile.
EDIT-(24May2016)- New CEO for June16 maybe reverse fortune...fell 9% to 17p.
EDIT(1Nov2016)-Bad Summer. PRM rose today to 6p. Oh deary.
EDIT(2Nov2016) -£3.2m@5p Rights-Huh- Why the slide is now revealed. It's 22% dilution-The timescale appears rushed... Anyone?
EDIT(30Dec2016)-Big Ann re Website - pres wh they've been spending investor money and PRM-management effort . . . www.proteomics.com. - does not work...Error msg 404 . . . what a waste of effort.... Wake Up PRM to the real World - and earn us some money from the trust we placed. sp 5.5p
EDIT (24April2017)- missed the AGM, because they don't send the paperwork any more . . . must have known it would be of little interest, etc. sp 5.5 could be worse? - at lest theior website is OK, but no mention of AGM, yesterday.
EDIT (30May2017)- sp down today (on small Vulpes Investment buy?) = 4.8p
EDIT (25July2017) - sp down 17% ( now 3.72p ). Management thinks results are in line...etc. Loss this time is 50k better than last. Oh dear.
EDIT (28July2017)-sp 3.6p...... Half-year results RNS [DYOR]:- T/O (similar to large corner-shop ), is smaller than losses, again - does no-one want this stuff?
EDIT:(7Nov2017)_ I mean their Testing-kits...or whatever..... BUT, there is the issue...as I find it difficult to say exactly "What" they are trying to sell.... Oh Dear.
Makes you want to weep, eh?
EDIT (6Jan2018)- down on Results, 2p8 - doesn't look good at all.

js8106455 - 30 May 2014 14:18 - 36 of 37

Listen: Proteome Science (PRM) - Preliminary results

Click here to listen
  • Page:
  • 1
  • 2
Register now or login to post to this thread.